p16INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome

International Journal of Gynecological Pathology

Volumn 23, Issue 4, 2004, Pages 354-365

  Branca, Margherita ^a   Ciotti, M ^b   Santini, D ^c   Di Bonito, L ^d   Giorgi, C ^a   Benedetto, A ^b   Paba, P ^b   Favalli, C ^b   Costa, S ^c   Agarossi, A ^e   Alderisio, M ^a   Syrjanen K ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Cervical cancer; CIN; Human papillomavirus; p16INK4a; Prognostic marker; Virus clearance Conization

Indexed keywords

CYCLIN D; DNA; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COLPOSCOPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 4644304965     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000139639.79105.40     Document Type: Article

References (58)

1. IARC. Monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Papillomaviruses. Lyon: IARC, 1995;1-409.
2. zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001;93:252-3.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
4. Syrjänen K, Syrjänen, S. Papillomavirus Infections in Human Pathology. Chichester: J. Wiley & Sons. 2000;1-615.
5. Aubin F, Pretet JL, Mougin C. Papillomavirus Humains Biologie et Pathologie Tumorale. Paris: Editions TEC & DOC, 2003;1-759.
6. Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
8. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
9. Giarre M, Caldeira S, Malanchi I, et al. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol 2001;75:4705-12.
10. Martin LG, Demers GW, Galloway DA. Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol 1998; 72:975-85.
11. Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res 2002;89:241-8.
12. Syrjänen SM, Syrjänen KJ. New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med 1999;31:175-87.
13. Kiyono T, Foster SA, Koop JI, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-8.
14. von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers 2001;17:123-8.
15. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25: 884-91.
16. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001;8:83-92.
17. Sano T, Masuda N, Oyama T, et al. Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 2002;52: 375-83.
18. Agoff SN, Lin P, Morihara J, et al. p16(INK4a) expression correlates with degree of cervical neoplasia: A comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003;16:665-73.
19. Cho NH. Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: Cyclin-dependent kinase inhibitors. Yonsei Med J 2002;43:722-8.
20. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
21. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
22. Sano T, Oyama T, Kashiwabara K, et al. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical mintraepithelial neoplasia. Pathol Int 1998;48:580-5.
23. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26: 1389-9.
24. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003;27:187-93.
25. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-5.
26. Masumoto N, Fujii T, Ishikawa M, et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 2003;34:778-83.
27. Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
28. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, et al. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61.
29. Saqi A, Pasha TL, McGrath CM, et al. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-70.
30. Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and Thin-Prep smears. J Clin Pathol 2003;56:56-63.
31. Nieh S, Chen SF, Chu TY, et al. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol 2003;91:201-8.
32. Pientong C, Ekalaksananan T, Swadpanich U, et al. Immunocytochemical detection of p16INK4a protein in scraped cervical cells. Acta Cytol 2003;47:616-23.
33. Kim JW, Namkoong SE, Ryu SW, et al. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol 1998;70:75-9.
34. Kim YT, Cho NH, Park SW, et al. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. Gynecol Oncol 1998;71:38-45.
35. Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80: 458-67.
36. Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 1999;96:12754-9.
37. Lu DW, El-Mofty SK, Wang HL. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA. Mod Pathol 2003;16:692-9.
38. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003;162: 747-53.
39. Fregonesi PA, Teresa DB, Duarte RA, et al. p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 2003;51:1291-7.
40. Branca M, Costa S, Mariani L, et al. Assessment of risk factors and Human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 2004;
41. Costa S, Terzano P, Santini D, et al. CD44 isoform 6 (CD44v6) is a prognostic indicators of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2001;80:67-73.
42. Costa S, Terzano P, Santini D, et al. Neoadjuvant chemotherapy in cervical carcinoma: Regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 2001;116:729-37.
43. Costa S, Simone PD, Venturoli S, et al. Factors predicting Human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 2003;90: 358-65.
44. Bauer HM, Greer CE, Manos M. Determination of genital human papillomavirus infection using consensus PCR. In: Herrington CS, McGee JOD, eds. Diagnostic Molecular Pathology: A Practical Approach. Oxford: Oxford University Press. 1992;132-52.
45. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-100.
46. Kleter B, van Doorn LJ, Scrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
47. Syrjänen KJ. Summary statement on prognostic factors in carcinoma of the uterine cervix. CME J Gynec Oncol 2003;8:298-301.
48. INK4a expression and integrated human papillomavirus oncogen transcripts in dysplastic lesions of the uterine cervix. CME J Gynec Oncol 2003;8:293-7.
49. Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127:959-68.
50. Syrjänen S, Shabalova IP, Petrovichev N, et al. Human Papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former Soviet Union. J Lower Genital Tract Dis 2002; 6:97-110.
51. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
52. dos Santos Silva I. Cancer Epidemiology: Principles and Methods. Lyon: IARC, 1999;367-71.
53. Nagai Y, Maehama T, Asato T, et al. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: Is it alarm for disease recurrence. Gynecol Oncol 2000;79:294-9.
54. Nobbenhuis MAE, Meijer CJLM, van den Brule AJC, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796-801.
55. Paraskevaidis E, Koliopuolos G, Alamanos Y, et al. Human papillomavirus testing in the prediction of the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2001;98: 833-6.
56. Acladious NN, Sutton C, Mandal D, et al. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002;98:435-9.
57. Syrjänen KJ, Erzen M. The prognostic significance of human papillomavirus (HPV) infections and cancer screening. CME J Gynec Oncol 2001;6:325-46.
58. Ferreux E, Lont AP, Horenblas S, et al. Evidence tor at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 2003;201:109-18.